CD52 and leukemia: Another gene commonly targeted for removal by gene editing agents in CAR therapy for leukemia is CD52. CD52 is the protein targeted by alemtuzumab, a chemotherapeutic agent commonly used in leukemia treatment, but which can also kill the transplanted CAR T cells.